Jiangsu Hengrui Medicine
600276.SS
#521
Rank
A$70.01 B
Marketcap
A$10.55
Share price
-0.04%
Change (1 day)
-20.40%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2026 (TTM): A$2.13 Billion

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings are A$4.79 Billion. In 2024 the company made an earning of A$1.49 Billion, an increase over its 2023 earnings that were of A$0.99 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) A$2.13 B
2024 A$1.49 B50.59%
2023 A$0.99 B11.35%
2022 A$0.89 B-13.91%
2021 A$1.03 B-34.08%
2020 A$1.56 B16.28%
2019 A$1.34 B32.92%
2018 A$1.01 B20.82%
2017 A$0.84 B23.8%
2016 A$0.67 B11.25%
2015 A$0.61 B39.52%
2014 A$0.43 B20.71%
2013 A$0.36 B11.46%
2012 A$0.32 B29.6%
2011 A$0.25 B31.28%
2010 A$0.19 B27.89%
2009 A$0.14 B5.84%
2008 A$0.14 B79.89%
2007 A$78.45 M32.93%
2006 A$59.02 M38.14%
2005 A$42.72 M21.56%
2004 A$35.14 M13.95%
2003 A$30.84 M38.06%
2002 A$22.34 M